

Corporate Funded Sponsored Projects Activity

Project Title	Funding Agency
A Multi-Center, Prospective, Randomized Trial Comparing the Peripheral I.V. Catheter Complication Rates of Two Different Catheter-Dressings	3M
Lipidomic applications in Trauma and Critical Care Research	AB SCIEX
Interleukin-18 blockade in a mouse of heart failure with preserved ejection fraction	AB2 Bio Ltd
Assessment of Harmonization of Serum Albumin Methods: State of the Art	Abbott Laboratories
Effects of medication candidates on responding maintained by cocaine and its conditional stimuli	AbbVie, Inc.
M12-665 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis Associated Pain	AbbVie, Inc.
M13-961: A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/ Ritonavir /ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARLE-III)	AbbVie, Inc.
Protocol No. M13-393 A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Coadministration of ABT-450 with Ritonavir (ABT-450/r) and ABT-267 in Adults with Chronic Hepatitis C Virus Infection (PEARL-I)	AbbVie, Inc.
USpella (Impella 2.5) Data Registry	Abiomed, Inc
Implementation & Evaluation of a Benefit Offset National Demonstration (BOND)	Abt Associates Inc.
Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficiency of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg twice daily) in Patients with Multiple Sclerosis.....Protocol #DER-401	Acorda Therapeutics, Inc.
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative PAH QuERI	Actelion
The Use of Star Polymers as Viscosity Modifiers, Dispersants, Antioxidants, and Detergents	Afton Chemical Corporation
Acute Kidney Injury N-gal Evaluation of Symptomatic heart failure Study (AKINESIS)... Protocol# DDDP-09EE-081	Alere
An Observational, Non-Interventional , Multi-Center, Multi-National Study of Patients with Atypical Hemolytic-Uremic Syndrome - Registry Protocol No. M11-001	Alexion Pharmaceuticals
Animal Care Services	Amercian International Biotechnology LLC
"START-CKD: Strategies Using Darbepoetin alfa to Avoid Transfusions in Chronic Kidney Disease." Protocol No. 20110226 Subproject for Institution # PT102264	Amgen, Inc.
A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Subproject for Institution # PT102264	Amgen, Inc.

Long Term Follow-Up Study of Patients with Hematologic	Amgen, Inc.
Master Clinical Trial Agreement	Amgen, Inc.
Fishery Entrainment Monitoring Plan	Arcadis
A Phase 3 Randomized, Open-Label Study of Ponatinib Versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase	ARIAD Pharmaceuticals, Inc.
Subproject for Institution # PT106191	Ascension Orthopaedics, Inc.
9463-CL-2303 Phase 3 Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis	Astellas Pharma Global Development, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-seronegative Kidney Transplant Recipients Receiving an Organ from a CMV-seropositive Donor	Astellas Pharma Global Development, Inc.
Master Clinical Study Agreement	Astellas Pharma Global Development, Inc.
Protocol #0113-CL-1004 "A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)"	Astellas Pharma Global Development, Inc.
A Randomized, Double-Blind, Multinational Study to Prevent Major Vascular Events with Ticagrelor Compared to Aspirin(ASA) in Patients with Acute Ischaemic Stroke or TIA [SOCRATES]	Astra Zeneca
GOG-3004: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy (D0818C0001)	Astra Zeneca
ASBI 801 - Simplified-STroke REhabilitation Assessment of Movement (S_STREAM) Scale in Subjects Obtained Between 24 and 48 Hours of a Non-hemorrhagic Ischemic Stroke..... Protocol #ASBI 801	Asubio Pharmaceuticals, Inc.
Multicenter, Open-label, Historically Controlled, Phase III Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Kedrion IVIG 10% in Adult and Pediatric Subjects with Primary Immunodeficiency (PID)- Protocol Number KB052	Atlantic Research Group
AtriCure Synergy Ablation Lesions for Non-Paroxysmal Forms of Atrial Fibrillation Treatment during Concomitant On-Pump Endo/Epicardial Cardiac Surgery	AtriCure, Inc.
A Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries....Protocol #CTP001-5	Avita Medical, LLC
A Prospective Clinical Evaluation of Biomarkers of Traumatic Brain Injury	Banyan Biomarkers, Inc.
A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter System	Bard Peripheral Vascular
A Tube-Deployed Dropsonde SUAS for extended Surface Sea Temperature Measurement	Barron Associates
Multi-modal Application for the Perception of Spaces (MAPS)	Barron Associates
Tube Launched UAV with Glide to Hover Transition	Barron Associates

Assessment of Tobacco Products Pharmacology and Behaviors	Battelle Memorial Institute
BAY 59-7939/14373 4-week, open-label, multiple-dose study of the safety and the pharmacokinetic and pharmacodynamic properties of the oral direct factor Xa	Bayer Inc.
A Phase II/III Multicenter, Partially Randomized, Open Label Trial Investigating Safety and Efficacy of On-Demand and Prophylactic Treatment with BAY 94-9027 in Severe Hemophilia A.....Protocol #BAY 94-9027...Subproject for Institution # PT104546	Bayer Inc.
A Randomized, Double-Blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients with Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases (BAY 73-4506/15983)	Bayer Inc.
An Open-Label Phase IIIb Study of Regorafenib in Patients with Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy...Protocol #BAY 73-4506/15967	Bayer Inc.
Master Clinical Trial Agreement	Bayer Inc.
A Randomized, Double Blind, Placebo Controlled Phase 3 Study to Investigate the Efficacy and Safety of Progesterone in Patients with Severe Traumatic Brain Injury	BHR Pharma, LLC
A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)	Biogen Idec, Inc.
A Multicenter, Open-Label, Single-Arm Study of Gastrointestinal Tolerability in Patients with Relapsing Forms of Multiple Sclerosis Receiving Tecfidera (dimethyl fumarate) Delayed-Release Capsules (MANAGE)	Biogen Idec, Inc.
Controlled High Risk AVONEX Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance: CHAMPIONS Continuation.....Protocol# US 04-09-AVX	Biogen Idec, Inc.
Master Agreement	Biogen Idec, Inc.
EP Fellowship 2014-2015	Biosense Webster, Inc.
NaviStar ThermoCool Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation PMA P0300031/S014	Biosense Webster, Inc.
nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation	Biosense Webster, Inc.
ThermoCool Smart Touch Catheter for the Treatment of Symptomatic Paroxysmal	Biosense Webster, Inc.
ThermoCool SmartTouch Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation - IDE Study - Study Start-up Documents	Biosense Webster, Inc.
SBIR Phase I: Development of a Highly Reliable Continuous Wireless Pressure Sensing System for Pediatric Intracardiac Monitoring	Biosensor Tech LLC
1241.36 A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended population of treatment naïve patients that includes those ineligible to receive peginterferon	Boehringer Ingelheim Pharmaceuticals, Inc.
A Phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 weeks in combination with pegylated interferon-a and ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C infection... Protocol#1220.47	Boehringer Ingelheim Pharmaceuticals, Inc.

Proposal to Evaluate the Development of a Heterogeneous Asymmetric Hydrogenation Catalyst	Boehringer Ingelheim Pharmaceuticals, Inc.
Safety and Efficacy of 240 mg BI 201335 Once Daily in Combination with Pegylated Interferon Alpha 2a and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV-co-Infected Patients.....Protocol #1220.19	Boehringer Ingelheim Pharmaceuticals, Inc.
Providing Direct Benefits Counseling in Support of the SSA BASS Efforts to Assist Beneficiaries to Pursue Their Employment Goals	Booz, Allen, Hamilton, Inc.
2014-2015 EP Fellowship	Boston Scientific
CAPT ure Information Via Automatic Threshold Evaluation (CAPTIVATE)	Boston Scientific
Image Ready™ MR Conditional Pacing System (SAMURAI)	Boston Scientific
Longitudinal Surveillance Study of the 4-SITE Lead/Header System (LSS of 4-SITE)	Boston Scientific
Multisensor Chronic Evaluations in Ambulatory Heart Failure Patients (MultiSENSE)	Boston Scientific
AIDS Clinical Trial Group Study Co-Chair	Brigham & Women's Hospital
Dapagliflozin Effect on Cardiovascular Events: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes (DECLARE TIMI58)-Prime Sponsor ASTRA ZENECA	Brigham & Women's Hospital
Evaluation of Yoga for Substance Use Risk Factors in the High School Setting	Brigham & Women's Hospital
Master Service Agreement CALGB/Case Study by BWH	Brigham & Women's Hospital
Master Agreement - Clinical Trial: PSA CALGB Member Institution #375: Cancer and Leukemia Group B Pathology Reimbursement	
Master Clinical Trial Agreement	Bristol-Myers Squibb Company
BTG-PR005-002- A Randomized, Double-Blind, Placebo-Controlled Study Comparing CroFabA versus Placebo with Rescue Treatment for Copperhead Snake Envenomation. BTG International=Sponsor, Chiltern=CRO	BTG International Inc.
A Randomized, Placebo Controlled Multi Center Study of the Efficacy PK and PD of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients	Cadence Pharmaceuticals, Inc.
S-ICD Post Approval Clinical Study (EFFORTLESS)	Cameron Health
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6-hour Intravenous Infusion of CXL-1427 in Hospitalized Patients with Systolic Heart Failure	Cardioxyl Pharmaceuticals, Inc.
A Phase 3, Multicenter, Randomized, Double-Blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-Dependent Anemia and Thrombocytopenia Due to IPSS Lower-Risk Myelodysplastic Syndromes	Celgene Corporation

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission	Celgene Corporation
A Phase II Study of the Use of 5-Azacitidine as Pre-Transplant Cyto-reduction Prior to Allogeneic Stem Cell Transplantation for High Risk Myelodysplastic Syndromes	Celgene Corporation
Master Clinical Study Agreement	Celgene Corporation
Cartilage Storage Solution for Chondrocyte Viability and Biomaterial Preservation	Cell & Tissue Systems
CellDex CDX301-03: CDX for the Mobilization and Transplantation of Allogeneic Blood Cell Grafts	CellDex Therapeutics
Clinical Education for VCU Family Medicine Residents FY15	Chippenham and Johnston Willis Hospital, Inc.
PARACHUTE IV: Percutaneous Ventricular Restoration in Chronic Heart Failure due to Ischemic Heart Disease SPONSOR: CardioKinetix (CRO: Clinipace)	Clinipace Worldwide
Master Research Agreement	Cochlear Americas
Master Agreement	Commonwealth Center for Advanced Logistics Systems (CCALS)
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Patients with Severe Alcoholic Hepatitis and Contraindications to Corticosteroid Therapy (TREAT-Mayo)	Conatus Pharmaceuticals Inc.
Post-Market Study Plan No. 12-013 "Zenapro™ Hybrid Hernia Repair Device for Ventral Hernia Repair"	Cook Biotech, Inc.
A Prospective, Randomized, Multi-Center, Double-Blind Trial to Assess the Effectiveness & Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT)...Protocol# P09-6301	Cordis Corporation
Stenting and Angioplasty with Projection in Patients at High Risk for Endarterectomy...Protocol #P06-3603-Sapphire WW	Cordis Corporation
CNDO 201 TRUST-I: A Phase II Study to Evaluate the Efficacy & Safety of 12 weeks of Treatment with Oral 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed By a 12 Week Open-Label Treatment Period in Patients with Moderately to Severely Active Crohn's Disease	Coronado Biosciences, Inc
A double-Blind, randomized, placebo-controlled, cross-over study to evaluate the clinical efficacy and safety of subcutaneous administration of human plasma-derived C1-esterase inhibitor in the prophylactic treatment of hereditary angioedema - Study No. CSL830_3001	CSL Behring
A Multi-Center, Partially Blinded, Maximum Tolerated Multiple Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety of GR-MD-02 in Subjects with Non-Alcoholic Steatohepatitis (NASH) with Advanced Hepatic Fibrosis (GT-020) SPONSOR: GALECTIN	CTI Clinical Trial and Consulting Services
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN305, a Humanised Monoclonal Antibody that Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function	CTI Clinical Trial and Consulting Services
Culpeper Downtown Enhancement Strategy	Culpeper Renaissance, Inc

A Multi-Center, Double-Blind, Randomized, Controlled Study to Determine the Safety and Pharmacokinetics of Ifetroban Injection in Hepatorenal Syndrome (CPT-IFE-001)	Cumberland Pharmaceuticals Inc.
Rheos Pivotal Trial	CVRx, Inc.
ENSURE in AF Study (Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of AF)	Daiichi Sankyo Pharma Development
RA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects with Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer (NSCLC)....Protocol #ARQ197-A-U302	Daiichi Sankyo Pharma Development
A Prospective, Multi-Center Study of Phasix Mesh for Ventral Incisional Hernia Repair, DVL-HE-011	Davol Inc.
Energy Harvesting: Developing Piezoelectric Materials for Passive Energy Harvesting	Dominion Energy, Inc.
Translational Study 5-Cholesten 3,25-diol 3-Sulfate as New Medicine for Therapy of Metabolic Disorders	DURECT Corporation
Measuring contact pathway biomarkers in subjects diagnosed with hereditary angioedema and non-HAE during and in between and acute attack, or diagnosed with other inflammatory diseases, using novel assays to measure protein markers of inflammatory disease biology, including plasma kallikrein and pK ₁ degradation products	Dyax Corp.
B067: Utility of fibroscan TM in the noninvasive assessment of liver disease	Echosens
Open Label Pilot Study W/an Extension Phase to Evaluate the Pharmacokinetics, and to Generate Preliminary Safety, Tolerability, Efficacy of Perampanel	Eisai, Inc.
CD INFORM - Investigating Natalizumab through further observational research and monitoring Protocol: ELN100226-CD451	Elan Pharmaceuticals
Translate-ACS Study. Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome....Protocol #H7T-US-B007	Eli Lilly
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Tecemotide Versus Placebo in Subjects with Completed Concurrent Chemo-Radiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)	EMD Serono, Inc
Master Agreement	EMD Serono, Inc
Non-Invasive Assay to Discriminate Between Mild Traumatic Brain Injury (mTBI) and Post-Traumatic Stress Disorder (PTSD)	Empirical Technologies Corporation
PROTOCOL EC-FV-06: A RANDOMIZED DOUBLE-BLIND PHASE 3 TRIAL COMPARING EC145 AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD/DOXIL/CAELYX) IN COMBINATION VERSUS PLD IN PARTICIPANTS WITH PLATINUM-RESISTANT OVARIAN CANCER	Endocyte, Inc
Subproject for Institution # PT105910	Entegron Inc
ReCharge	EnteroMedics
Content Evaluation of the Gastroparesis Cardinal Symptom Index-Daily Diary for Use in Patients Diagnosed with Parkinson's Disease and Gastroparesis	Evidera
High Flow Humidification Therapy in Cystic Fibrosis	Fisher & Paykel Healthcare, Ltd

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study with Vilazodone in Patients with Major Depressive Disorder	Forest Research Institute
A Randomized, Multicenter, Open-Label Trial Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines As Adjuvant Therapy in Patients with Operable Her2-Positive Primary Breast Cancer	Genentech, Inc.
Richmond Defense & Veterans Brain Injury Center	General Dynamics Information Technology
Choosing Neoadjuvant Chemotherapy versus Hormonal Therapy for Breast Cancer Base (MCC-13311)/ PI Initiated	Genomic Health, Inc.
Defibrotide for Patients with Hepatic Veno-Occlusive Disease: A Treatment IND Study	Gentium
Reduced Intensity Myeloablative Total Body Irradiation and Thymoglobulin Followed by Allogeneic Peripheral Blood Stem Cell Transplantation	Genzyme Corporation
SVCARB07609 Efficacy and Safety of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients with Chronic Kidney Disease	Genzyme Corporation
(GS-US-321-0106) A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like Molecule 2 (LOXL2) in Subjects with Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH).	Gilead Sciences, Inc.
A Phase 2, Randomized. Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis	Gilead Sciences, Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas Aeruginosa Infection in Subjects with Cystic Fibrosis	Gilead Sciences, Inc.
A Randomized, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy... Protocol# GU-US-300-0140	Gilead Sciences, Inc.
GS-US-248-0122: A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection	Gilead Sciences, Inc.
comments: HCV Registry Extension protocol for subjects that achieved an SVR	
GS-US-337-0108: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ? Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection	Gilead Sciences, Inc.
GS-US-337-0115 (ION 4) A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects with Chronic Genotype 1 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection	Gilead Sciences, Inc.
GS-US-337-0123: A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who have Advanced Liver Disease or are Post-Liver Transplant	Gilead Sciences, Inc.
GS-US-352-0101: A Phase 3, Randomized, Double-blind, Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)	Gilead Sciences, Inc.

Master Clinical Trial Agreement	Gilead Sciences, Inc.
Protocol GS-US-248-0123, "A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection	Gilead Sciences, Inc.
Protocol GS-US-321-0102 A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like Molecule 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC)	Gilead Sciences, Inc.
Protocol GS-US-321-0105 A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety, and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like Molecule 2 (LOXL2) in Subjects with Advanced Liver Fibrosis but not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH). - Subproject for Institution # PT103761	Gilead Sciences, Inc.
Heterogeneous Oxidation in Catalysis in Continuous Flow	GlaxoSmithKline
MMR-160 GSK Biologicals' MMR Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine as a First Dose Both Co-Administered with Varivax, Havrix and Prevnar 13 (Subset of Children) to Healthy Children 12 to 15 Months of Age	GlaxoSmithKline
Treatment of Patients with Pulmonary Arterial Hypertension and Right Heart Failure.	GlaxoSmithKline
James River Water Quality Monitoring	Greeley and Hansen LLP
Alpha-1 Anti-Tripsin (AAT) in ST-Segment Elevation Acute Myocardial Infraction (STEMI)	Grifols, Inc.
Confidential Disclosure Agreement- (GT11307) A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiac Surgery with Cardiopulmonary Bypass'	Grifols, Inc.
Master Collaboration Agreement	Health Diagnostic Lab, Inc.
2014-2015 Heart Failure Fellowship	HeartWare
HQP 1001-SCD-007 - A Randomized, Placebo-Controlled, Phase 2 Study of HQK-1001 in Sickle Cell Disease	HemaQuest
CMV-Neutralizing Activity of PC-Based Vaccines	Hookipa Biotech AG
Treatment of Wound Infection with Novel Uncharged Silver Carbene Complexes	IASIS Molecular Sciences
A Multicenter Open-Label Extension Study for Subjects Who Participated in Study B0151003 (ADANTE II) Protocol: B0151005	ICON Clinical Research, Inc.
PRIDE-HD: A Phase 2 Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients with Huntington's Disease	ICON Clinical Research, Inc.
Protocol #A3921095....Study of Oral CP-690, 550 as an induction therapy in subjects with moderate to severe ulcerative colitis	ICON Clinical Research, Inc.
Protocol# B0151003 A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04236921 IN SUBJECTS WITH CROHNS DISEASE WHO ARE ANTI-TNF INADEQUATE RESPONDERS (ANDANTE)	ICON Clinical Research, Inc.

V419-006 Phase III of V419 in Healthy Infants when given at 2, 4 and 6 months concomitantly with Prevnar 13 and Rota Teq	ICON Clinical Research, Inc.
Evaluation of the Safety and Efficacy of the OPTIMIZER II System with Active Fixation Leads in Subjects with Heart Failure Resulting from Systolic Dysfunction: FIX-HF-5	Impulse Dynamics, Inc.
INCB 18424-268: A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer	Incyte Corporation
A Phase 2 Multicenter, Single Dose, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Evaluating the Safety and Efficacy of Two Doses of Stannosoporphin in Combination with Phototherapy in Neonates. Protocol No. 64,185-204	Infacare Pharmaceutical Corporation
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.....Protocol #PIPE-016	InterMune, Inc.
A Treatment Protocol to Allow Patients in the US with Idiopathic Pulmonary Fibrosis Access to Pirfenidone Protocol No. PIPF-031	InterMune, Inc.
An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies	InterMune, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Study of the Efficacy of Intranasal Midazolam in the Outpatient Treatment of Subjects with Seizure Clusters (ARTEMIS 1): P261-401 (SPONSOR: UPSHER SMITH)	inVentiv Health Inc.
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Risk of Recurrence.....Protocol# REMICADE CRD3001	Janssen Biotech, Inc.
Training Course for Continuous Regional Anesthesia for Rib Fractures-Tunnel Catheter Placement Technique	Kimberly-Clark Corporation
Kuwait Training Gate-Training and Technical Assistance	Kuwait Training Gate
Subproject for Institution # PT106389	Kuwait Training Gate
Brain-Computer Interface-based Volition Control Device	Ladenburg Funding, Inc. (The)
Cloud Based Collaboration for Clinical Trials, Research and Training	Leidos Biomedical Research
The Tissue and Data Acquisition and Analysis Core (TDAAC) to Provide Clinical Specimens in Support of NCI's Clinical Assay Development Program (CADP) Projects	Leidos Biomedical Research
PROPOSAL TO TEST Lu AA21004 AND OTHER COMPOUNDS IN A SUSTAINED ATTENTION TASK (VISUAL SIGNAL DETECTION)IN RATS	Lundbeck, Inc.
YES Graduate Program	Maersk
Evaluation of Purified Poloxamer 188 in Children in Crisis (Epic): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of ANX-188 (Purified Poloxamer 188) Injection in Children with Sick Cell Disease Experiencing Vaso-Occlusive Crisis	Mast Therapeutics, Inc
Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sick Cell Disease (EPIC): A Phase 3, Randomized, Double Blind, Placebo-Controlled Multicenter Clinical Trial of MST-188 (purified poloxamer 188) Injection in Subjects with Sick Cell Disease Experiencing Vaso-Occlusive Crisis	Mast Therapeutics, Inc

Disability Research Consortium (DRC)	Mathematica Policy Research, Inc.
Health Quality Research (Interest Funded Projects)	Mathematica Policy Research, Inc.
NIHCR Health Policy Research, Inc.	Mathematica Policy Research, Inc.
Redesigning Diabetes Work Processes for Population-based Primary Care	Mathematica Policy Research, Inc.
Safety Net Hospitals and the ACA	Mathematica Policy Research, Inc.
An Observational Study to Evaluate the Relationship of Nasal Mucus Properties and Symptoms in Acute Rhinosinusitis	McNeil Consumer Healthcare
Effect of Long Acting Antihistime on Opioid-Induced Pruritus: A Double-Blind Placebo Controlled Study	McNeil Consumer Healthcare
PINCER Based In-Process Analyzer for Manufacturing of Biologics	Mediomics, LLC
Artifact-free Cone-beam CT Construction for Pedicle Screw and DBS Probe Localization	Medtronic
Endeavor Drug eluting stenting: Understanding Care, Antiplatelet agents and Thrombotic Events (EDUCATE).....Protocol# IP114	Medtronic
EP Fellowship 2014-2015	Medtronic
PainFree SST Clinical Study Medtronic	Medtronic
Renal Denervation in Patients with Uncontrolled Hypertension (Symplicity HTN-3)....Protocol #IP125	Medtronic
A phase I Randomized, Double Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of the Human CMV Vaccine(V160) in Healthy Adults	Merck & Co., Inc.
A Phase III, Double Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)....Protocol #V212-001	Merck & Co., Inc.
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001 AM2) (MODIFY I)	Merck & Co., Inc.
Immune Responses to CMV in Pregnancy	Merck & Co., Inc.
Evaluation of Presidio and Cerecyte Coils in Large and Giant Aneurysms - PAC Registry	Micrus Endovascular Corporation
A Phase 3, Randomized, Double-Blind Multicenter Study Comparing Oral MLN9708 C16014 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma	Millennium Pharmaceuticals
MCC 03740: Phase 1 Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma	Millennium Pharmaceuticals
Phase I Trial of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma....Protocol #RM-CLL-PI-0006	Millennium Pharmaceuticals
DAR Services for Molecules for Health	Molecules for Health
Continuous Production of Cobalt Nanoparticles	Nanofoundry, LLC.
Evaluation of Oral Antibiotic Use with Nasal Saline Irrigation for the Treatment of Rhinosinusitis	NeilMed Pharmaceuticals, Inc.

A Prospective Controlled Post-Approval Study of NeoMend ProGEL Sealant in the Treatment of Visible Pleural Air Leaks after Standard Pleural Closure	Neomend, Inc.
Confidential Disclosure Agreement - "A Prospective, Randomized Study to Compare Progel® Sealant to Gelfoam® Plus as an Adjunct for the Control of Bleeding after Conventional Hemostasis in Subjects Undergoing Thoracic Aortic Surgery," NEO13-100	Neomend, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients with Traumatic Injury (TBI)	Neuren Pharmaceuticals Limited
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Docetaxel in Combination with 1-methyl-D-tryptophan (indoximod) in Metastatic Breast Cancer	NewLink Genetics Corporation
A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute Pancreatic Cancer Vaccine in Subjects with Surgical Resected Pancreatic Cancer....Protocol #NLG0405	NewLink Genetics Corporation
NNS RFQ# 6000435719, Independent Study on the Licensing Feasibility of Advanced Nuclear Reactor Concepts Using Natural Circulation	Newport News Shipbuilding
Robotics for Tank Inspection Phase 2	Newport News Shipbuilding
A 24 month, randomized, controlled study to evaluate the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus compared to standard tacrolimus in recipients of living donor liver transplants. (RAD001H)	Novartis Pharmaceuticals Corporation
A 24-Week, open-label, parallel-group, interventional phase IV study comparing Tobramycin Inhalation Powder administration once daily continuously versus TIP administration bid in 28 day on/off cycles for the treatment of pulmonary Pseudomonas Aeruginosa in patients with Cystic Fibrosis	Novartis Pharmaceuticals Corporation
A 5-year, Prospective, Non-Intentional Multicenter Registry in Sickle Cell Disease patients...Protocol# C1CL670AUS38...Subproject for Institution # PT102299	Novartis Pharmaceuticals Corporation
A Phase II Randomized, Multicenter Study of Treatment-free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 after Switching to Nilotinib	Novartis Pharmaceuticals Corporation
A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients with ALK-rearranged (ALK-positive) Advanced Non-Small Cell Lung Cancer Who Have Been Treated Previously with Chemotherapy (Platinum Doublet) and Crizotinib	Novartis Pharmaceuticals Corporation
A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-Myocardial Infarction Patients with Elevated hsCRP....Protocol # CACZ885M2301.....Subproject for Institution # PT102299	Novartis Pharmaceuticals Corporation
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients with Non-alcoholic Fatty Liver Disease (NAFLD)	Novartis Pharmaceuticals Corporation
CTBM100C2412: A multi-center, human factors engineering (HFE) usability study in cystic fibrosis patients to validate the approved instructions for use (IFU) of TOBI Podhaler (tobramycin inhalation powder) using placebo capsules	Novartis Pharmaceuticals Corporation

Interleukin-1 blockade with Canakinumab to Improve Exercise Capacity in Patients with Chronic Systolic Heart Failure and Elevated hs-CRP. A Randomized, Double-blind, Placebo-controlled, Event Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events..... Protocol #CACZ885M2301 CANTOS SubStudy	Novartis Pharmaceuticals Corporation
Master Agreement	Novartis Pharmaceuticals Corporation
Serelaxin Therapy for Ischemic Cardiomyopathy	Novartis Pharmaceuticals Corporation
Subproject for Institution # PT102299	Novartis Pharmaceuticals Corporation
A single arm, phase II, open-label study to determine the efficacy of 100 mg twice daily oral dosing of Midostaurin administered to patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an Associated Hematological Clonal Non-Mast Cell Lineage Disease	
A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity of ProQuad Vaccine When Administered Concomitantly with Novartis Meningococcal ACWY Conjugate Vaccine to Healthy Toddlers - Protocol V59P21	Novartis Vaccines and Diagnostics
A Phase 3b, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine when Administered with Routine Infant Vaccinations to Healthy Infants. Protocol No. V59P23	Novartis Vaccines and Diagnostics
Master Clinical Trial Agreement	Novartis Vaccines and Diagnostics
A Self Assembling Gel with Antimicrobial and Antioxidant Properties for Burns	Novion Technologies
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial On Safety of Monthly Therapy with rFXIII in Subjects with Congenital FXIII Deficiency...Protocol# F13CD-3720	Novo Nordisk Pharmaceuticals, Inc.
Impact of Coated Platelet Levels on rFVIIa Response as Measured by Thrombin Generation and Platelet Function	Novo Nordisk Pharmaceuticals, Inc.
Master Clinical Trial Agreement	Novo Nordisk Pharmaceuticals, Inc.
Surveillance of Safety and Efficacy of Wilate in Patients with Von Willebrand Disease (Wil 20)	Octapharma Incorporated
"Clinical Trial of the On-X Valve using low Dose Anticoagulation"	On-X Life Technologies
Phase 2 Study of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain (Reolysin) in Combination with Paclitaxel and Carboplatin in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Have KRAS or EGFR Activated Tumors... Protocol# REO 16	Oncolytics Biotech, Inc.
Randomized, Double-Blind, Multicenter Two-Stage Adaptive Phase II Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination with Paclitaxel and Carboplatin versus the Chemotherapy Alone in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck Who Have Progressed on or after Prior Platinum-Based Chemotherapy... Protocol# REO 18	Oncolytics Biotech, Inc.
Preclinical Studies Examining Interactions Between the HDAC Inhibitor Vorinostat and the Proteasome Inhibitor Carfilzomib in Malignant Human Hematopoietic Cells in Vivo and in Vivo	Onyx Pharmaceuticals, Inc.
Multi-Center Phase 3 Trial of Minocycline HC1 1mg Microspheres for the Use in Subjects with Peri-Implantitis: Clinical and Microbiological Evaluations	OraPharma Inc

Cannabinoid Receptor Agonists for Treatment of Chronic Pain	Organix, Inc.
An Observational Prospective Registry to Identify Demographic and Clinical Characteristics of Patients Hospitalized with Euvolemic and Hypervolemic Hyponatremia and Assess the Comparative Effectiveness of Available Treatments and the Impact on Resource Utilization....Protocol #156-10-292	Otsuka Pharmaceutical Development & Commercialization, Inc.
A Selective Metabolic Approach to Increase Phenylephrine Oral Bioavailability, Part 1: Establish the Approach	Pfizer Inc., U.S. Pharmaceuticals Group
An Open-Label, Multicenter, Multiple-Dose Pharmacokinetic and 48-Week Safety and Efficacy Trial of Maraviroc in Combination with Optimized Background Therapy for the Treatment of Antiretroviral-Experienced CCR5-Tropic HIV-1 Infected Children 2-18 Years of Age	Pfizer Inc., U.S. Pharmaceuticals Group
Master Clinical Trial Agreement	Pfizer Inc., U.S. Pharmaceuticals Group
Protocol #A3921139....A Multi-Center, Open-Label Study of CP-690, 550 In Subjects With Moderate to Severe Ulcerative Colitis (OCTAVE)	Pfizer Inc., U.S. Pharmaceuticals Group
Protocol #A7281009-9002:A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-00547659 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (TURANDOT)...Subproject for Institution # PT106040	Pfizer Inc., U.S. Pharmaceuticals Group
Protocol A7281010: A Multicenter Open-Label Extension Study to Assess Long-Term Safety of PF-00547659 in Subjects with Ulcerative Colitis (TURANDOT II)... Subproject for Institution # PT106040	Pfizer Inc., U.S. Pharmaceuticals Group
A Multi-Center, Randomized. Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of R04995819 Versus Placebo, as Adjunctive Therapy in Patients with Major Depressive Disorder Having Inadequate Response to Ongoing Antidepressant Treatment - Protocol No. BP25712	Pharmaceutical Research Associates
A Two Part, Phase 1, Multicenter, Open-Label, Study of DKN-01 Given Intravenously Part A: A Dose Escalation Study in Patients with Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients with Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)	Pharmaceutical Research Associates
A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765) in Combination with Carfilzomib (Kyprolis) in Subjects with Relapsed and Refractory Multiple Myeloma	Pharmacyclics, Inc
Pharmacyclics Master Agreement	Pharmacyclics, Inc
COPD Wet & Dry Weight	Philips Healthcare
Philips Master Agreement	Philips Healthcare
Image-guided Radiation Therapy and Brachytherapy: a Virtual Clinical Trial Database for Locally Advanced Cervical Cancer & Intermediate Risk Prostate Cancer	Philips Radiation Oncology Systems
A 14 Month Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate teh Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures	PPD Development, LLC
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair (PPD)	PPD Development, LLC

An Open Label, Multicenter, Follow-Up Trial to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose Up to a Maximum of 150mg/day in Subjects Aged 16 Years or Older Suffering from Epilepsy	PPD Development, LLC
A Study to Evaluate the Efficacy and Safety of GFT505 80mg & GFT505 120mg once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH). Protocol GFT505-212-7	Premire Research International LLC
Monitoring Plan for Diadromous Fishes in Curles Neck Creek, James River Basin, Virginia	Pruitt Companies
A Four-Year Blinded-Outcomes Follow-Up Study of Patients Who Received Stannosporfin or Placebo in Clinical Trial - Protocol No. 64,185-205	Quintiles, Inc.
A Phase 3, Double-Blind, Randomized, Efficacy and Safety and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease	Quintiles, Inc.
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises.	Quintiles, Inc.
A Randomized, Double-Blind, Controlled, Multi-Center Phase 2 Study to Evaluate the Effect of Roflumilast Plus Pioglitazone on Liver Enzymes and Liver Fat Content in Subjects with Nonalcoholic Steatohepatitis", ROF-NASH-205	Quintiles, Inc.
Multicenter, Open-label, Safety and Pharmacokinetic Study of Oral Codeine Sulfate Administration in Pediatric Subjects 2 Years Old Through 17 Years Old With Post-Procedural Pain	Quintiles, Inc.
Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering From Acute Decompensated Heart Failure [TRUE AHF] SPONSOR: CARDIORENTIS	Quintiles, Inc.
AQT90 FLEX BNP Reference Interval DC-047163	Radiometer Medical
AQT90 FLEX BNP, NT-proBNP Method Comparison Style	Radiometer Medical
A Point-Prevalence Study to Evaluate the Prevalence of Antibodies to Selected Porcine Viruses in Patients with Cystic Fibrosis Who Are Receiving Porcine-Derived Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors	REGISTRAT-MAPI
Respicardia Inc. Pivotal Trial of the remede System Clinical Investigational P1	Respicardia
RFHE 4043: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, & Pharmacokinetics of Rifaximin 550 mg in Subjects with Severe Hepatic Impairment & Overt Hepatic Encephalopathy	Salix Pharmaceuticals, Inc.
RFHE4043PK- RIFAXIMIN 550 MG with Severe Hepatic impairment and overt hepatic encephalopathy	Salix Pharmaceuticals, Inc.
RFHE4044: A MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF RIFAXIMIN 550 MG WITH AND WITHOUT LACTULOSE IN SUBJECTS WITH A HISTORY OF RECURRENT OVERT HEPATIC ENCEPHALOPATHY ("Study")	Salix Pharmaceuticals, Inc.
RNLC2131: A Randomized, Double-Blind, Placebo-Controlled, Dose-ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets For the Prevention of Complications in Subjects with early DECompensated Liver Cirrhosis	Salix Pharmaceuticals, Inc.

A prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients (TERI-PRO)	Sanofi US
A Randomize, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Efficacy & Safety of SAR339658 in Patients With Active Moderate to Severe Ulcerative Colitis (UC)	Sanofi US
A randomized, double-blind, placebo controlled, parallel group, multicenter study to evaluate the cardiovascular outcomes during treatment with lixisenatide as an add-on to standard of care treatment in type 2 diabetic patients after an acute coronary syndrome...Protocol# EFC11319 (LIXA STUDY)... Subproject for Institution # PT102597	Sanofi US
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome (ODYSSEY)	Sanofi US
An International, Multi-Center Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two-Year Treatment with Teriflunomide 7 mg Once Daily and 14 mg, Once Daily, Versus Placebo in Patients with a clinical Episode Suggestive of Multiple Sclerosis Plus a Long-Term Extension Period..... Protocol #EFC6260....Subproject for Institution # PT102597	Sanofi US
Master Agreement Sanofi US Services Inc.	Sanofi US
Evaluation of the Beckman Coulter DxN HCV Viral Load Assay as an Aid in the Management of HCV-Infected Individuals Undergoing Antiviral Therapy....Protocol #HCV-01-11....Subproject for Institution # PT106001	SC Liver Research Consortium, LLC.
Master Agreement	SC Liver Research Consortium, LLC.
IMPROVE-IT.....Protocol #P0413	Schering
A Phase 2 Single-Arm, Open-Label Study of Single-Agent Brentuximab Vedotin for Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above	Seattle Genetics
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 (Brentuximab Bedotin) and Best Supportive Care (BSC) versus Placebo and BSC in the Treatment of Patients at High Risk of Residual Lymphoma (HL) Following Autologous Stem Cell Transplant (ASCT)	Seattle Genetics
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and VHP (A+CHP) versus CHOP in the Frontline Treatment of Patients with CD30-positive Mature T-cell Lymphomas: the ARROVEN Study	Seattle Genetics

JL Note: 5 year term

Master Agreement Effective date: November 15, 2012

Master agreement is effective thru November 14, 2017.

Phase 2 Study of Brentuximab Vedotin with RCHOP for Diffuse Large B-Cell Lymphoma (Protocol SGN35-017)	Seattle Genetics
--	------------------

SGN35-016 A Phase 1/2 Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination with Bendamustine in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL)	Seattle Genetics
--	------------------

SenoRx Contura Overnight Treatment Trial: Safety and Feasibility of Short-Course, Accelerated, Hypofractional Partial Breast Radiotherapy in Women with early Stage Breast Cancer Using the Contura: A Phase II Trial Protocol# S09-001	SenoRx
---	--------

Siemens Master Research Agreement	Siemens Medical Systems, Inc.
-----------------------------------	-------------------------------

Master Agreement: Siemens Software Grant for VCU Engineering Education	Siemens PLM Software
--	----------------------

Siemens Software Grant for VCU Engineering Education	Siemens PLM Software
--	----------------------

Master Agreement CRB SSS-S-13-003178: Influenza Studies IRC003 and IRC004 Domestic Operation	Social & Scientific Systems, Inc.
--	-----------------------------------

Protocol IRC 003 entitled, "A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) versus Oseltamivir for the Treatment of Influenza	Social & Scientific Systems, Inc.
---	-----------------------------------

Evaluating the use of polymyxin B Hemoperfusion in a Randomized controlled trial of adults treated for endotoxemia and septic shock...Protocol: SDI-PMX-NA001	Spectral Diagnostics Inc.
---	---------------------------

A Multicenter, Open Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma....Protocol# PXD101-CLN-19	Spectrum Pharmaceuticals
---	--------------------------

MCC-12517: Phase I Study of Belinostat and Bortezomib in Relapsed or Refractory Acute Leukemia/Myelodysplastic Syndrome Protocol: MCC-12517	Spectrum Pharmaceuticals
---	--------------------------

A Prospective, Randomized, Controlled Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Single-Lobe Treatment of Severe Emphysema	Spiration, Inc.
--	-----------------

Engaging Teachers to Accelerate English Language Learner's Progress (ETAELLP)	State Council of Higher Education for Virginia
---	--

Subproject for Institution # PT109331	State Council of Higher Education for Virginia
---------------------------------------	--

C-Pulse System US IDE Study	Sunshine Heart Inc.
-----------------------------	---------------------

RA-142: SynCardia Freedom Driver System Study	SynCardia Systems, Inc.
---	-------------------------

The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) Postmarket Surveillance Study	SynCardia Systems, Inc.
---	-------------------------

A multinational, multicenter, randomized, parallel-group STUDY PERFORMED IN SUBJECTS WITH Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) injection 40 mg administered three times a week, compared to placebo in a double-blind design....(Subproject for Institution # PT103086)...Protocol# MS-GA-301	Teva Neurosciences, Inc.
Driveline Silicone Skin Interface (SSI) Registry Protocol	Thoratec Corporation
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients...Protocol #ROADMAP	Thoratec Corporation
Safety and Efficacy of Octreotide in Left Ventricular Assist Device (LVAD) Associated Gastrointestinal (GI) Bleeding-CSMS995AUS63T (NOVARTIS providing drug)	Thoratec Corporation
TH-CR-406/SARC021 - A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma	Threshold Pharmaceuticals
A Non-Interventional, Long-Term, Post Marketing registry of Patients Treated with CIMZIA for Crohns Disease....Protocol #C87075	UCB BioSciences, Inc.
Protocol #SP0980 - Open Label Single-Arm, Explorative Study to Evaluate Tolerability and Efficacy of Locosamide When Added to Levetiracetam (VERVE)	UCB BioSciences, Inc.
The effect of rotigotine on motor symptoms in patients with advanced Parkinson's Disease with motor fluctuations and gastroparesis Phase 3B Study (SP1055 Study)	UCB BioSciences, Inc.
Research & Engineering Services for Dept. of Energy's NETL	URS Corporation
Task 3 Quantifying complex fluid-phase properties at high pressure/high temperature Subproject for Institution # PT106172	URS Corporation
Task Order 7 - Experimental Density Data for Hydrocarbon Mixtures at HTHP	URS Corporation
Master Varian Agreement	Varian Medical Systems
VMA - P6: Dose Reconstruction for MR-guided Intracavitary Brachy.....Subproject for Institution # PT105301	Varian Medical Systems
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lumacaftor Monotherapy, and Lumacaftor and Ivacaftor Combination Therapy in Subjects With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation - Protocol No. VX09-809-102	Vertex Pharmaceuticals, Inc
VX11-770-108 Part B Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation	Vertex Pharmaceuticals, Inc
VX11-770-109 - A Phase 3, 2-Arm, Roll-Over Study to Evaluate the Long-term Safety and Pharmacodynamics of Ivacaftor Treatment in Pediatric Subjects With Cystic Fibrosis and a CFTR Gating Mutation	Vertex Pharmaceuticals, Inc
VX11-950-115 Telaprevir in combination with Peginterferon Alfa-2a and Ribavirin in Subjects coinfectd with Genotype 1 HCV and HIV-1	Vertex Pharmaceuticals, Inc
VX12-770-112 - A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long-Term Ivacaftpr Treatment in Subjects 6 Years of Age and Older with Cystic Fibrosis and a Non-G551D CFTR Mutation	Vertex Pharmaceuticals, Inc

VX12-809-105 - A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation	Vertex Pharmaceuticals, Inc
Medicaid Patient-Centered Medical Home: Costs, Outcomes, and Challenges	Virginia Premier Health Plan, Inc.
Comparison of non-invasive clinical thermometers to Core Gold Standard.	Welch Allyn, Inc.
Outcomes AlloMap Registry (OAR) Study	XDx Incorporated
Hospital Wearable Defibrillator Inpatient Study	Zoll